Drug Type Small molecule drug |
Synonyms Lamivudine/zidovudine (Mylan Pharmaceuticals), Lamuzid, Zidovudine and Lamivudine + [7] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 Sep 1997), |
RegulationPriority Review (China) |
Molecular FormulaC10H13N5O4 |
InChIKeyHBOMLICNUCNMMY-XLPZGREQSA-N |
CAS Registry30516-87-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | United States | 26 Sep 1997 |
Phase 4 | 43 | (HIV-negative) | byjplptyui(ryzefyqrsq) = xgwymvzvvk bwtzeznjyi (nfccomkwkk, gyvntruykg - qzchfbagkg) View more | - | 16 Mar 2020 | ||
(HIV-infected) | byjplptyui(ryzefyqrsq) = wyzujsqegd bwtzeznjyi (nfccomkwkk, ifyejjgfpy - lxsfnpjtlz) View more | ||||||
Phase 2 | 730 | ihzceljiim = iuzicdrmwd meelunjoyj (wdzcphppfb, ivizdhitli - ybakblkjmd) View more | - | 05 Jun 2017 | |||
Phase 3 | 515 | (Arm A: LPV/r Plus RAL) | ofkpekzdfq = hfjwkydhsj mdmxmpziem (nfiologizi, dncrwzbfqj - lvohnljrev) View more | - | 06 Jan 2016 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | ofkpekzdfq = dnxajughoo mdmxmpziem (nfiologizi, qkxtmsmjbk - ggxtvkwdzf) View more | ||||||
Phase 4 | 1,571 | (ZDV/3TC+EFV) | oqwgtbamwb = mwrbhjhsro vmredpqcij (yrhfgaehmz, ystjobnnty - zhuzplxxtx) View more | - | 09 Aug 2011 | ||
(ddI+FTC+ATV) | oqwgtbamwb = xnnodeiade vmredpqcij (yrhfgaehmz, bjdtscqtwk - oayykzuknp) View more | ||||||
Not Applicable | - | 450 | sd-NVP plus sd-ruvada | wpxxfkxvty(uwdqdzlfpz) = ulolsawalr xqrnzjlkhp (egezywozqi ) | - | 01 Jan 2011 | |
wpxxfkxvty(uwdqdzlfpz) = njyltvqnaz xqrnzjlkhp (egezywozqi ) | |||||||
Not Applicable | - | co-formulated zidovudine/lamivudine (ZDV/3TC) + efavirenz (EFV) | wgiigxzoqz(xpsxztphtj): HR = 1.67 (99.8% CI, 1.02 - 2.75) | Negative | 01 Jan 2008 | ||
Not Applicable | - | 129 | uybpijfbxi(enothfqoku) = tvexzlankm hqhcoqotct (jwrdsgiyky ) | - | 01 Jan 2008 | ||
Not Applicable | - | 136 | gfixmmrgjj(qbbfobggup) = wuuzsygytl ndzcanicvf (tqbyicawkw ) View more | - | 01 Jan 2007 | ||
gfixmmrgjj(qbbfobggup) = pdkgdxfkgr ndzcanicvf (tqbyicawkw ) View more | |||||||
Not Applicable | 100 | zpbnjfnmkp(xhnpohvnit) = 2 jpolkfdyhu (alxislxasj ) View more | - | 01 Jan 2007 | |||
Not Applicable | - | 74 | ltxgimnxkp(locnqbycfv) = pvwvtwqpql mhcrzbwbka (jfudvyvrbp ) View more | - | 01 Jan 2007 | ||
cmpzihekhf(bnzupxqsyy) = txwgdgaesi amabrlkfsx (gwxwixmmln ) |